Skip to main
LYEL

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lyell Immunopharma's financial position exhibits strength, with cash, cash equivalents, and marketable securities increasing to $320 million, bolstered by a recent private placement, despite modest increases in operating expenses. The company is experiencing optimistic developments in its clinical pipeline, particularly highlighted by the potential of LYL273, which shows promise in achieving durable complete responses in challenging patient populations. Additionally, expert feedback has reinforced the company's competitive edge in the CAR-T market, indicating significant opportunities for growth and an increased probability of regulatory approval for its therapies.

Bears say

The financial outlook for Lyell Immunopharma appears negative primarily due to significant risks associated with its product pipeline and overall market growth potential. A decrease in research and development expenditures from $34.9 million in 2Q25 to $28.2 million in 3Q25 indicates potential operational challenges or reduced commitment to advancing critical clinical trials. Furthermore, concerns surrounding the durability of efficacy and safety management for its assets, specifically LYL273, hinder investor confidence, particularly as current data does not provide sufficient evidence to substantiate the therapy's effectiveness in the competitive landscape of CAR-T treatments.

Lyell Immunopharma (LYEL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.